Healthspan vs. Lifespan: What Investors and Operators Need to Understand

Lifespan is how long you live; healthspan is how long you live in good health — and the two have come apart. Globally, people now spend an average of 9.6 years living with disease or disability before they die, a gap that has widened over the past two decades. For anyone building, investing, or operating in aging and longevity, that gap is not a sad statistic. It is the market. The value in this sector is being created less by adding years to life and more by adding health to the years we've already added.

If you take one strategic idea from this, make it that one. Here's why it matters and how to act on it.

What's the difference between healthspan and lifespan?

Lifespan, or life expectancy, is the familiar number: how many years a person is expected to live. Healthspan is the number of those years lived in good health, free of significant disease or disability. The technical proxy researchers use is health-adjusted life expectancy (HALE) — life expectancy discounted for years lived in poor health.

The headline finding from the 2024 Mayo Clinic study in JAMA Network Open, covering 183 WHO member states, is that these two measures have diverged. Between 2000 and 2019, global life expectancy rose by about 6.5 years, but health-adjusted life expectancy rose by only 5.4. We've been manufacturing additional years faster than we've been making them healthy. The result is the healthspan-lifespan gap — and it's growing.

Why does the gap matter strategically?

Because it tells you where unmet need — and therefore durable value — actually sits.

A market organized around lifespan optimizes for extending life: acute care, disease treatment, end-of-life intervention. A market organized around healthspan optimizes for compressing the years of poor health: prevention, early detection, functional maintenance, chronic-disease management, and quality of life. The widening gap is a signal that the second market is where the pressure — clinical, economic, and human — is concentrating.

This also reframes what "longevity" should mean commercially. The popular framing of longevity as life-extension — living to 100, 120, beyond — captures attention but misreads the opportunity. The larger, more fundable, more reimbursable problem is the 9.6 years, not the extra decade at the far tail. Products and services that shrink the gap address a need every health system and family already feels.

Where is the gap widest — and what does that signal?

Strikingly, the gap is largest in wealthy nations. The Mayo analysis found the widest healthspan-lifespan gaps in the United States, Australia, New Zealand, the UK, and Norway, with the US the widest of all — for American women, roughly the last 12.4 years of life are on average affected by disease or disability. The smallest gaps appear in some of the poorest countries, where lifespan itself is shorter.

For strategy, this carries two implications. First, the most acute healthspan problem sits in the highest-spending healthcare markets — meaning the buyers with budgets are also the buyers with the largest unmet need. Second, the gap is notably wider for women, who carry a heavier later-life burden of noncommunicable disease; products and research that have historically under-served women's later-life health are addressing a measurable, under-met market.

How should this shape decisions?

A few principles we apply in advisory work:

• Underwrite to healthspan, not lifespan. When evaluating a company or a market, ask what it does to the quality-adjusted years — does it compress the period of poor health? That's where reimbursement logic and human need align.
• Prevention and function are the growth vectors. The gap is widened by chronic disease, frailty, sensory and cognitive decline. Solutions that delay or compress these map directly onto the problem health systems are being crushed by.
• Follow the budgeted need, not the dramatic narrative. Life-extension makes headlines; healthspan makes purchase orders. The institutional buyers are organizing around quality-adjusted outcomes and total cost of care.
• Treat the policy shift as a tailwind. Researchers and governments are increasingly calling for a pivot from reactive treatment to proactive, wellness-centric care. Companies positioned on the healthspan side of that pivot are moving with the current.

The healthspan-lifespan gap is the rare statistic that doubles as a strategy. It tells you that the central problem of modern aging is no longer how to live longer — we've largely solved that — but how to live well for the years we've gained. The organizations that internalize that, and build for the gap rather than the tail, are the ones aligned with where this market is actually heading.

The science of compressing that gap — what actually preserves cognitive and physical function — is the domain of our intelligence partner, Brain Meets Bytes; see Can Alzheimer's Be Prevented? for one piece of it.

Frequently asked questions

What is the difference between healthspan and lifespan? Lifespan is how long you live; healthspan is how long you live in good health, free of significant disease or disability. The technical measure for healthspan is health-adjusted life expectancy (HALE).

How big is the healthspan-lifespan gap? Globally, about 9.6 years as of 2019, according to a 2024 Mayo Clinic study of 183 WHO member states — and widening. The gap is largest in wealthy countries, with the United States the widest, and is generally larger for women than men.

Why does the healthspan-lifespan gap matter for business and policy? It identifies where unmet need is concentrating: not in extending life further, but in compressing the years of poor health. That points value toward prevention, early detection, and functional maintenance, and supports a policy shift toward proactive, wellness-centric care.

Work with us: Kairahn helps investors and operators read the longevity market and position for where value is actually being created. Start a conversation.